You just read:

New Data Highlighting in vitro Potency Advantages for VIBATIV® (telavancin) Against Difficult-to-Treat MRSA and MSSA Pathogens Reported at ASM Microbe 2017

News provided by

Theravance Biopharma, Inc.

Jun 05, 2017, 08:30 ET